Based on the aggregated intelligence of 165,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, laboratory services provider Genoptix (Nasdaq: GXDX) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Genoptix's business and see what CAPS investors are saying about the stock right now.

Genoptix facts

Headquarters (Founded)

Carlsbad, Calif. (1999)

Market Cap

$309.0 million


Health care services

Trailing-12-Month Revenue

$192.6 million


Founder/CEO Dr. Tina Nova 

CFO Douglas Schuling

Return on Equity (Average, Past 3 Years)



$132.4 million / $0


LabCorp (NYSE: LH)

Genzyme (Nasdaq: GENZ)

Bio-Reference Labs

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 99% of the 231 All-Star members who have rated Genoptix believe the stock will outperform the S&P 500 going forward. These bulls include Beorn10 and zzlangerhans, both of whom are ranked in the top 10% of our community.

Last month, Beorn10 tapped Genoptix's first-quarter earnings miss as a "can't miss" opportunity: "Seems like a profitable small company who did not manage analyst expectations very well. With the sell off today this appears to be a good entry point into this value play, which may eventually morph into a growth stock if they continue to show good profitability."

Unfortunately, Genoptix has continued to disappoint Mr. Market since that pitch, with the most recent letdown being a double-digit slash to both its full-year revenue and earnings outlook. In fact, Genoptix shares have been cut by more than half over the past three months, while its bigger lab services competitors LabCorp and Genzyme have basically been flat during the same period. Of course, with Genoptix now trading even with LabCorp and at a substantial discount to Genzyme on a forward price-to-earnings basis, CAPS All-Stars such as zzlangerhans are carefully starting to kick its tires:

I'm stepping gingerly into Genoptix here as it's a little outside my usual sphere of influence. I looked over their products and services last night and they do seem to be offering a slick package. Overall, I'm skeptical of the thesis that a temporary economic decline will significantly impact health care spending, which is what seems to be weighing heavily on stocks like Myriad Genetics, Genomic Health, and Genoptix. Of course, continued pessimism could make this a long-term pick.

What do you think about Genoptix, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. LabCorp is Motley Fool Stock Advisor pick. Genomic Health is a Rule Breakers recommendation. The Fool owns shares of Bio-Reference Labs. The Fool's disclosure policy always gets a perfect score.